Global Bipolar Disorder Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs.

By Mechanism of Action;

Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Tricyclic Antidepressant Drugs, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta Blockers, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn957445998 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Bipolar Disorder Market (USD Million), 2021 - 2031

In the year 2024, the Global Bipolar Disorder Market was valued at USD 5,573.94 million. The size of this market is expected to increase to USD 6,402.71 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 2%.

The Global Bipolar Disorder Market, a complex mental health condition characterized by periods of mania and depression, is a multifaceted landscape encompassing pharmaceuticals, psychotherapeutic interventions, and supportive care. Bipolar disorder affects millions worldwide, posing significant challenges to individuals, families, and healthcare systems alike. This introduction serves as a gateway to understanding the intricate dynamics shaping the global bipolar disorder market.

Bipolar disorder, formerly known as manic-depressive illness, is a chronic psychiatric disorder marked by alternating episodes of mania or hypomania and depression. These mood swings can range from extreme highs of elevated energy, euphoria, and irritability to profound lows of sadness, hopelessness, and lethargy. The disorder's severity, duration, and frequency of mood episodes vary widely among individuals, necessitating tailored treatment approaches.

The Global Bipolar Disorder Market encompasses a spectrum of interventions aimed at managing symptoms, stabilizing mood, and improving overall quality of life. Pharmaceutical therapies, including mood stabilizers, antipsychotics, antidepressants, and adjunctive medications, form the cornerstone of treatment. Additionally, psychotherapy, such as cognitive-behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and family-focused therapy (FFT), play pivotal roles in addressing the psychological and interpersonal aspects of the disorder.

Beyond pharmacological and psychotherapeutic modalities, the bipolar disorder market extends to supportive interventions and lifestyle modifications. These may include psychoeducation, self-management strategies, lifestyle adjustments, and community-based support services aimed at fostering resilience, enhancing coping skills, and promoting recovery.

Navigating the market involves understanding the interplay of various factors, including epidemiological trends, treatment paradigms, regulatory frameworks, reimbursement policies, and advancements in research and innovation. As stakeholders strive to address the unmet needs of individuals living with bipolar disorder, the market continues to evolve, presenting both challenges and opportunities for improved care delivery and patient outcomes.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Mechanism of Action
    3. Market Snapshot, By Region
  4. Global Bipolar Disorder Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising bipolar disorder prevalence and diagnosis rates
        2. Increasing mental health awareness and recognition
        3. Advances in bipolar disorder treatments
        4. Aging population contributing to disorder incidence
      2. Restraints
        1. Mental health stigma impacting help-seeking
        2. Limited access to mental healthcare
        3. Medication side effects and safety concerns
        4. Diagnosis and subtype differentiation challenges
      3. Opportunities
        1. Biomarker and genetic testing integration
        2. Research for treatment response predictors
        3. Early intervention and preventive strategies adoption
        4. Complementary therapy integration
        5. Holistic bipolar disorder management approaches adoption
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Bipolar Disorder Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Mood Stabilizer
      2. Anticonvulsants
      3. Antipsychotic Drugs
      4. Antidepressant Drugs
      5. Antianxiety Drugs
    2. Global Bipolar Disorder Market, By Mechanism of Action, 2021 - 2031 (USD Million)
      1. Selective Serotonin Reuptake Inhibitor
      2. Serotonin Norepinephrine Reuptake Inhibitor
      3. Tricyclic antidepressant Drugs
      4. Monoamine Oxidase Inhibitor
      5. Benzodiazepines
      6. Beta Blockers
      7. Others
    3. Global Bipolar Disorder Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca PLC
      2. GlaxoSmithKline PLC
      3. Pfizer Inc.
      4. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
      5. Bristol Myers Squibb Company
      6. Eli Lilly and Company
      7. Novartis International AG
      8. AbbVie Inc.
      9. Allergan PLC
      10. Otsuka Pharmaceutical Co. Ltd
      11. Lundbeck A/S
      12. Sunovion Pharmaceuticals Inc
      13. Takeda Pharmaceutical Company Limited
      14. Mylan N.V. (Viatris Inc.)
      15. Alkermes PLC
  7. Analyst Views
  8. Future Outlook of the Market